AU2002339680A1 - Agonists and antagonists of bromix for the treatment of metabolic disorders - Google Patents

Agonists and antagonists of bromix for the treatment of metabolic disorders

Info

Publication number
AU2002339680A1
AU2002339680A1 AU2002339680A AU2002339680A AU2002339680A1 AU 2002339680 A1 AU2002339680 A1 AU 2002339680A1 AU 2002339680 A AU2002339680 A AU 2002339680A AU 2002339680 A AU2002339680 A AU 2002339680A AU 2002339680 A1 AU2002339680 A1 AU 2002339680A1
Authority
AU
Australia
Prior art keywords
bromix
agonists
antagonists
treatment
metabolic disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002339680A
Inventor
Kristen Briggs
Deno Dialynas
John Lucas
Aaron Scalia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Publication of AU2002339680A1 publication Critical patent/AU2002339680A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
AU2002339680A 2001-12-26 2002-10-14 Agonists and antagonists of bromix for the treatment of metabolic disorders Abandoned AU2002339680A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34420601P 2001-12-26 2001-12-26
US60/344,206 2001-12-26
PCT/IB2002/004603 WO2003055509A1 (en) 2001-12-26 2002-10-14 Agonists and antagonists of bromix for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
AU2002339680A1 true AU2002339680A1 (en) 2003-07-15

Family

ID=23349502

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002339680A Abandoned AU2002339680A1 (en) 2001-12-26 2002-10-14 Agonists and antagonists of bromix for the treatment of metabolic disorders

Country Status (2)

Country Link
AU (1) AU2002339680A1 (en)
WO (1) WO2003055509A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112410B1 (en) 2001-08-29 2006-09-26 Human Genome Sciences, Inc. Human tumor necrosis factor TR21 and methods based thereon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1033134T3 (en) * 1997-10-29 2007-07-16 Otsuka Pharma Co Ltd Compositions that inhibit smooth muscle proliferation and method for diagnosing arteriosclerosis
EP1085897A4 (en) * 1998-05-21 2003-03-12 Smithkline Beecham Corp Acrp30r1l, a homolog of acrp30 (30 kd adipocyte complement-related protein)
AU5129800A (en) * 1999-05-11 2000-11-21 Incyte Genomics, Inc. Extracellular matrix and adhesion-associated proteins
EP1185645A1 (en) * 1999-05-27 2002-03-13 ZymoGenetics, Inc. Adipocyte complement related protein homolog zacrp7
WO2001051645A1 (en) * 2000-01-14 2001-07-19 Genset Obg3 globular head and uses thereof for decreasing body mass
UA83458C2 (en) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
US20030092164A1 (en) * 2000-11-07 2003-05-15 Gross Jane A. Human tumor necrosis factor receptor

Also Published As

Publication number Publication date
WO2003055509A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
AU2002339691A1 (en) Agonists and antagonists of prolixin for the treatment of metabolic disorders
AU2003223579A1 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
IL209842A0 (en) Compounds for the treatment of metabolic disorders
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
AU2002363935A1 (en) Composition and method for the treatment of anorectal disorders
AU2002339673A1 (en) Agonists and antagonists of ryzn for the treatment of metabolic disorders
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
AU2002363228A1 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
AU2002339680A1 (en) Agonists and antagonists of bromix for the treatment of metabolic disorders
AU2002339682A1 (en) Emergen agonists and antagonists for use in the treatment of metabolic disorders
AU2002339681A1 (en) Agonists and antagonists of glucomin for the treatment of metabolic disorders
AU2002321761A1 (en) Agonists and antagonists of disomet for the treatment of metabolic disorders
AU2002321766A1 (en) Agonists and antagonists of obesingen for the treatment of metabolic disorders
AU2002339685A1 (en) Agonists and antagonists of oxifan for the treatment of metabolic disorders
AU2002321770A1 (en) Agonists and antagonists of genceptin for the treatment of metabolic disorders
AU2002313580A1 (en) Xobesin agonists and antagonists for the treatment of metabolic disorders
AU2002324297A1 (en) Agonists and antagonists of moxifin for the treatment of metabolic disorders
AU2002321769A1 (en) Agonists and antagonists of cobesin for the treatment of metabolic disorders
AU2002324300A1 (en) Agonists and antagonists of moceptin for the treatment of metabolic disorders
AU2002329001A1 (en) Agonists and antagonists of cylixin for the treatment of metabolic disorders
AU2002339683A1 (en) Agonist and antagonists of redax for the treatment of metabolic disorders
AU2002321767A1 (en) Tr xidatin agonists and antagonists treatment of metabolic disorders
AU2002339668A1 (en) Treatment of metabolic disorders with xitar agonists and antagonists
AU2002324296A1 (en) Agonists and antagonists of energen for use in the treatment of metabolic disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase